The present invention relates to highly modular amphiphilic polymer-dendron hybrids comprising hydrophobic dendrons conjugated to hydrophilic polymers that can be synthesized with a high degree of structural freedom, for suspending SWCNTs in aqueous solution. Utilizing the susceptibility of the polymer-dendrons towards enzymatic degradation, the present invention provides methods of detecting the presence of an enzyme in a sample as well as methods of monitoring of enzymatic activity by changes in the SWCNT fluorescent signal.

Preparing a dendritic tag includes forming a liquid composition including dendrites, separating the dendrites from the liquid composition, and disposing the dendrites on a substrate. In some cases, the composition is applied to a substrate and the liquid is evaporated to yield at least one dendrite in direct contact with the substrate. A labeled item includes an item and a dendritic tag coupled to the item, such that the item can be identified or authenticated based on a property of the dendritic tag.

Compositions may include those of the formula: (I) wherein R1 is an alkyl chain having a carbon number in the range of greater than 40 to 200, R2 is a multiester, R3 is hydrogen, an ion, or an alkyl chain having a carbon number in the range of 1 to 200, m is an integer selected from 0 to 4, and n is an integer selected from the range of 0 to 4, wherein the sum of m and n is 1 or greater. Compositions may include a reaction product of a polyisobutylene-substituted succinic anhydride and a hydroxy-functional dendrimer, wherein the molar ratio of polyisobutylene-substituted succinic anhydride to hydroxy-functional dendrimer is within the range of 10:1 to 30:1. ##STR00001##

A nanoglue is formed with one or more bioadhesive polymers, one or more dendrimers, and optionally one or more therapeutic, prophylactic, or diagnostic agents. The bioadhesive polymers and dendrimers are modified with functional groups to permit crosslinking upon one or more stimuli, e.g., ultraviolet irradiation, and form hydrogel in situ at tissue sites. In the repair of corneal wounds, the nanoglue leads to improved rate of healing with less scarring and less inflammation, compared to non-treated cornea or ones treated with sutures. Therapeutic agents can be covalently conjugated to the precursor components and be delivered to specific eye compartments, providing a more efficacious treatment formulation of ocular disorders than delivering drugs in their free forms. Methods of making and using the hydrogel and hydrogel precursor compositions are also provided.

This disclosure relates to polymers and polymer compositions having monomer units of polyoxometalates and monomer units comprising hydroxy-terminated molecules such as branched molecules or dendrimers and uses in degradation, decontamination, and deodorization. In certain embodiments, the hydroxy-terminated branched molecules or dendrimers comprise terminal 1,1-tris(hydroxymethyl)methyl or 1,1,1-tris(hydroxyalkyl)methyl groups. In certain embodiments, the hydroxy-terminated molecule is N,N′,N″-tris[tris(hydroxymethyl) methyl]-1,3,5-benzenetricarboxamide.

The present invention provides a cyanine modified telodendrimer, nanoparticles thereof, and methods of using the nanoparticles to treat various diseases such as cancer.

The invention relates to polymer-interaction molecule (e.g., antibodies) conjugates and uses of such conjugates for delivery of interaction molecules to cells. The invention also relates uses polymer-interaction molecule (e.g., antibodies) conjugates for eliciting cellular responses (e.g., induction of cell proliferation).

Provided herein is a dendrimer comprising: i) a core unit (C); and ii) building units (BU), wherein the core unit is covalently attached to at least two building units; the dendrimer having from two to six generations of building units; wherein building units of different generations are covalently attached to one another; and the dendrimer further comprising: iii) one or more first terminal groups attached to an outermost building unit, wherein each first terminal group comprises a radionuclide-containing moiety; and iv) one or more second terminal groups attached to an outermost building unit, wherein each second terminal group comprises a pharmacokinetic-modifying moiety; or a salt thereof. Also provided are compositions comprising the dendrimers, and methods of using the dendrimers and compositions in diagnostic and therapeutic applications.

Compositions may include those of the formula: (I) wherein R1 is an alkyl chain having a carbon number in the range of greater than 40 to 200, R2 is a multiester, R3 is hydrogen, an ion, or an alkyl chain having a carbon number in the range of 1 to 200, m is an integer selected from 0 to 4, and n is an integer selected from the range of 0 to 4, wherein the sum of m and n is 1 or greater. Compositions may include a reaction product of a polyisobutylene-substituted succinic anhydride and a hydroxy-functional dendrimer, wherein the molar ratio of polyisobutylene-substituted succinic anhydride to hydroxy-functional dendrimer is within the range of 10:1 to 30:1.

##STR00001##

Provided herein are compositions and nanocarriers comprising linear-dendritic telodendrimers (TD) containing riboflavin. The nanocarriers and compositions have desirable loading properties and stabilized structure and can be used for efficient in vivo delivery.